Centessa Pharmaceuticals plc (CNTA)
|52 Week Range||2.885-13.83|
|1y Target Est||-|
|DCF Unlevered||CNTA DCF ->|
|DCF Levered||CNTA LDCF ->|
|Debt / Equity||28.54%||Neutral|
Upgrades & Downgrades
Latest CNTA news
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC f...
3 November 2022
New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentation New efficacy and safety data from 18-m...
Wall Street Analysts Predict a 128% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Her...
23 June 2022
The mean of analysts' price targets for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) points to a 127.7% upside in the stock. While this highly sought-after metric has not proven reasonably effect...
BMO Capital Sees Almost 300% Upside On Centessa Stock
17 June 2022
BMO Capital has initiated coverage on Centessa Pharmaceuticals plc (NASDAQ: CNTA) with a price target of $19 (293% upside), and an Outperform rating. The analyst writes that ZF874 is a differentiated ...
Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day
23 March 2022
BOSTON and LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the Guggenheim Ge...
Centessa Pharmaceuticals (CNTA) Sees Hammer Chart Pattern: Time to Buy?
24 November 2021
Centessa Pharmaceuticals (CNTA) has been struggling lately, but the selling pressure may be coming to an end soon.
Centessa Pharmaceuticals to Present at Upcoming Conferences in 2021
10 November 2021
BOSTON and LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA) today announced that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the fo...
Why Did Centessa's Shares Plunge 10% Today?
1 November 2021
Centessa Pharmaceuticals plc (NASDAQ: CNTA) announced proof-of-mechanism data from the first three subjects in Phase 1 Part B study of ZF874 in Alpha-1 Antitrypsin Deficiency (AATD). AATD is an autos...
Centessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital
4 October 2021
~ New $300 million facility, combined with Company's cash balance as of June 30, 2021, provides access to over $900 million to advance development programs and enable pursuit of strategic business dev...
Here's why Centessa Pharma is up 20% on Thursday morning
9 September 2021
Centessa Pharmaceuticals PLC – ADR (NASDAQ: CNTA), in partnership with its subsidiary ApcinteX Limited announced that results from its ongoing first-in-human proof-of-concept study to analyze SerpinPC...